"Paralyzing Uncertainty" Does Not Create Declaratory Judgment Jurisdiction
Client Alert | 1 min read | 09.04.08
In Prasco, LLC v. Medicis Pharmaceutical Corporation and Imaginative Research Associates, Inc. (No. 07-1524; August 15, 2008), the Federal Circuit further clarifies the scope of declaratory judgment jurisdiction in patent cases. The Federal Circuit explains that although the Supreme Court found that an actual controversy can exist when there is no apprehension of suit in MedImmune Inc. v. Genentech, Inc., 127 S. Ct. 764 (2007), "it did not change the bedrock rule that a case or controversy must be based on a real and immediate threat of future injury that is caused by defendants - an objective standard that cannot be met by a purely subjective or speculative fear of future harm."
Prasco filed for a declaratory judgment that its benzoyl peroxide cleansing product did not infringe four patents listed on Medicis' competing benzoyl peroxide product. Prasco claimed that although it had not yet begun marketing its product, it had devoted substantial efforts to development and marketing plans and that it suffered "paralyzing uncertainty" from fear that Medicis would sue for patent infringement.
In affirming the district court's dismissal, the Federal Circuit finds Prasco's paralyzing uncertainty argument insufficient, noting that a patentee's marking of its products with applicable patent numbers provides little, if any, evidence that the patentee will ever enforce its patents. Thus, patent marking is irrelevant to the question of an imminent threat of harm sufficient to create an actual controversy. The Court also indicates that although failure to sign a covenant not to sue is a circumstance to be considered, it is not sufficient on its own to create an actual controversy. The Court explains that some affirmative action by patentee is usually necessary to create such a controversy and that a patentee has no obligation to spend the time and money to test a competitor's product nor to make a definitive determination, at a competitor's request, that it will never bring an infringement suit. In fact, where a competitor does approach a patentee with such a request, the patentee's silence does not alone make an infringement action or other interference with the competitor's business imminent and does not confer declaratory judgment jurisdiction.
Contacts
Insights
Client Alert | 3 min read | 04.14.26
On Friday, April 10, 2026, the U.S. Department of Justice (DOJ) announced that International Business Machines Corporation (IBM) has agreed to pay just over $17 million to resolve allegations that it violated the False Claims Act (FCA) by failing to comply with federal anti-discrimination requirements incorporated into its federal contracts due to allegedly discriminatory diversity, equity, and inclusion (DEI) employment practices. This resolution marks the first FCA settlement secured by the DOJ under its Civil Rights Fraud Initiative, created in May 2025, and announced by then-Deputy Attorney General Todd Blanche as part of the administration’s coordinated efforts to target allegedly unlawful DEI practices. Per the agreement, the settlement is neither an admission of liability by IBM nor a concession by the United States that its claims are not well founded.
Client Alert | 4 min read | 04.14.26
FedRAMP Solicits Public Comment on Overhaul to Incident Communications Procedures
Client Alert | 5 min read | 04.14.26
Client Alert | 4 min read | 04.14.26

